Study provides additional support for use of new class of diabetes drugs

September 24, 2020

A new study led by a cardiologist from Brigham and Women's Hospital has assessed the cardiovascular and renal outcomes for ertugliflozin, an SGLT2 inhibitor prescribed for patients with type 2 diabetes to help them control blood sugar levels. The Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial (VERTIS CV) found that the drug had a safety profile similar to that of other SGLT2 inhibitors and did not increase risk of major adverse events compared to the placebo. The results did not show a statistically significant benefit, but, taken together with other recent studies of SGLT2 inhibitors, the study results add to a growing body of evidence that supports guidelines for using this class of drugs to help prevent adverse cardiovascular outcomes. The findings of their study were published in the New England Journal of Medicine.

"This class of medications has turned out to be a huge win for patients with benefits beyond blood glucose control," said Christopher Cannon, MD, a cardiologist at the Brigham. "Originally, the Food and Drug Administration had requested analyses of the safety of these medications, but studies have found that rather than causing harm, SGLT2 inhibitors show beneficial effects, lowering risk of adverse cardiovascular and renal outcomes."

Type 2 diabetes can lead to heart failure hospitalization and renal disease progression, with adult type 2 diabetic patients and their clinicians often navigating cardiovascular and renal concerns while working to control blood sugar levels. Recent studies of other SGLT2 inhibitors have found that they may provide a benefit to both renal and cardiovascular health.

VERTIS-CV relied on an event-driven, noninferiority structure, which was revised in the wake of a positive trial involving another drug in the class. In light of the positive outcomes of that EMPA-REG trial, the VERTIS-CV team doubled its sample size and reduced the time left in the trial from five years to an average of three years. Of the 8,238 patients enrolled in the trial, the average age was 64.4 and average length of type 2 diabetes diagnosis was 13 years.

Previous studies have established ertugliflozin as an effective medication for controlling blood sugar levels. VERTIS-CV assessed the drug's cardiovascular safety. Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was non-inferior to placebo for the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke -- an endpoint known as MACE. Overall, major adverse cardiovascular outcomes occurred in about 12 percent of patients in both the ertugliflozin and placebo groups. A combination of both cardiovascular death or hospitalization for heart failure occurred in about 8 percent and 9 percent in the ertugliflozin and placebo groups, respectively. A secondary endpoint of hospitalization for heart failure showed a 30 percent lower rate with ertugliflozin.

Ertugliflozin is the fourth drug in this class to be tested on such a large scale and demonstrate noninferiority against a placebo. The three other major SGLT2 drug trials -- testing dapagliflozin, canagliflozin, and empagliflozin -- produced significant benefits across different endpoints.

The American Diabetes Association guidelines established in 2019 recommend the use of SGLT2 inhibitors such as ertugliflozin in type 2 diabetes patients as an additional agent for lowering blood sugar and for lowering risk of cardiovascular and renal events in patients predisposed to these complications. Cannon describes his team's results as supportive of these guidelines.

"The guidelines, if anything, were a little bit ahead of their time and are spot on," said Cannon.

"These data reaffirm the guidelines, and now it's on us as clinicians to more completely follow the guidelines."
-end-
Cannon, C.P. et al. "Ertugliflozin and Cardiovascular Outcomes in Type 2 Diabetes" New England Journal of Medicine DOI: 10.1056/NEJMoa2004967

Brigham and Women's Hospital

Related Science Articles from Brightsurf:

75 science societies urge the education department to base Title IX sexual harassment regulations on evidence and science
The American Educational Research Association (AERA) and the American Association for the Advancement of Science (AAAS) today led 75 scientific societies in submitting comments on the US Department of Education's proposed changes to Title IX regulations.

Science/Science Careers' survey ranks top biotech, biopharma, and pharma employers
The Science and Science Careers' 2018 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.

Science in the palm of your hand: How citizen science transforms passive learners
Citizen science projects can engage even children who previously were not interested in science.

Applied science may yield more translational research publications than basic science
While translational research can happen at any stage of the research process, a recent investigation of behavioral and social science research awards granted by the NIH between 2008 and 2014 revealed that applied science yielded a higher volume of translational research publications than basic science, according to a study published May 9, 2018 in the open-access journal PLOS ONE by Xueying Han from the Science and Technology Policy Institute, USA, and colleagues.

Prominent academics, including Salk's Thomas Albright, call for more science in forensic science
Six scientists who recently served on the National Commission on Forensic Science are calling on the scientific community at large to advocate for increased research and financial support of forensic science as well as the introduction of empirical testing requirements to ensure the validity of outcomes.

World Science Forum 2017 Jordan issues Science for Peace Declaration
On behalf of the coordinating organizations responsible for delivering the World Science Forum Jordan, the concluding Science for Peace Declaration issued at the Dead Sea represents a global call for action to science and society to build a future that promises greater equality, security and opportunity for all, and in which science plays an increasingly prominent role as an enabler of fair and sustainable development.

PETA science group promotes animal-free science at society of toxicology conference
The PETA International Science Consortium Ltd. is presenting two posters on animal-free methods for testing inhalation toxicity at the 56th annual Society of Toxicology (SOT) meeting March 12 to 16, 2017, in Baltimore, Maryland.

Citizen Science in the Digital Age: Rhetoric, Science and Public Engagement
James Wynn's timely investigation highlights scientific studies grounded in publicly gathered data and probes the rhetoric these studies employ.

Science/Science Careers' survey ranks top biotech, pharma, and biopharma employers
The Science and Science Careers' 2016 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics.

Three natural science professors win TJ Park Science Fellowship
Professor Jung-Min Kee (Department of Chemistry, UNIST), Professor Kyudong Choi (Department of Mathematical Sciences, UNIST), and Professor Kwanpyo Kim (Department of Physics, UNIST) are the recipients of the Cheong-Am (TJ Park) Science Fellowship of the year 2016.

Read More: Science News and Science Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.